Limiting systemic endocrine overtreatment in postmenopausal breast cancer patients with an ultralow classification of the 70-gene signature.
M OpdamV van der NoortM KleijnA GlasI MandjesS KleiterpF S HilbersD T KrugerA D BinsP C de JongP P J B M SchiphorstT van DalenB FlamelingR C RietbroekA BeekerS M van den HeiligenbergS D BakkerA N M WymengaI M OvingR M BijlsmaP J van DiestJ B VermorkenH van TinterenSabine C LinnPublished in: Breast cancer research and treatment (2022)
These survival analyses indicate that the postmenopausal node-negative ER+HER2- patients with an ultralow-risk 70-gene signature score have an excellent 10-year DRFI after surgery with a median of 1 year of endocrine treatment. This is in line with published results of the STO-3-randomized clinical trial and supports the concept that it is possible to reduce the duration of endocrine treatment in selected patients.